1
|
Platelet Apoptotic Response May Be Associated With the Capacity of Aspirin to Inhibit Platelets. J Cardiovasc Pharmacol 2021; 76:584-591. [PMID: 33170592 DOI: 10.1097/fjc.0000000000000908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
An inadequate platelet response to aspirin (ASA) has been identified in some patients under chronic ASA treatment. The aim of this study was to analyze if ASA-sensitive and ASA-resistant platelets have differences in their apoptotic capability. Clinically stable ischemic coronary patients who had been taking ASA (100 mg/d) for at least 9 months before inclusion were divided into ASA-resistant (n = 11) and ASA-sensitive (n = 13) groups as defined by the PFA-100 test. Platelets from ASA-sensitive patients showed higher expression of the proapoptotic proteins Bak and Bax than those from ASA-resistant patients, although only Bak protein remained different when the results were adjusted by age. In resting platelets, neither caspase-3 activity nor cytosolic cytochrome C levels were different between both experimental groups. Stimulation of platelets with calcium ionophore (10 nmol/L, A23187) increased caspase-3 activity (1.91-fold higher; P < 0.05) and cytosolic cytochrome C levels (1.84-fold higher; P < 0.05) to a higher degree in ASA-sensitive than in ASA-resistant platelets. In conclusion, ASA-sensitive platelets seem to be better prepared to undergo apoptosis during robust platelet activation.
Collapse
|
2
|
Zamorano-León JJ, Ballesteros S, de Las Heras N, Alvarez-Sala L, de la Serna-Soto M, Zekri-Nechar K, Freixer G, Calvo-Rico B, Yang Z, García-García JM, Lahera V, López-Farré AJ. Effect of Pectin on the Expression of Proteins Associated with Mitochondrial Biogenesis and Cell Senescence in HT29-Human Colorectal Adenocarcinoma Cells. Prev Nutr Food Sci 2019; 24:187-196. [PMID: 31328124 PMCID: PMC6615348 DOI: 10.3746/pnf.2019.24.2.187] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Accepted: 04/02/2019] [Indexed: 01/08/2023] Open
Abstract
Mitochondria dynamic is regulated by different proteins, maintaining a balance between fission and fusion. An imbalance towards mitochondrial fission has been associated with tumor cell proliferation. The aim of this study was to analyze whether pectin modifies the viability of human colon cancer cells and the expression of proteins involved in mitochondrial fusion and fission. The human colon carcinoma cell line HT29 cells was growth in 10% fetal bovine serum in the absence and presence of pectin. Pectin reduced HT29 cell viability in a concentration-dependent manner, reaching a plateau at 150~300 μmol/L pectin. The presence of 200 μmol/L pectin reduced the expression of dynamin-related protein-1 and increased expression of the mitochondrial fusion-associated proteins mitofusin-1 and 2. Expression of cyclin B1, a protein involved in G2/M transition, was found decreased in pectin-incubated HT29 cells. Moreover, expression of p53 protein, the amount of p53 in the nucleous and β-galactosidase activity, which are all biomarkers for cellular senescence, were significantly higher in pectin-incubated HT29 cells than in HT29 cells incubated without pectin. Expression of the protein B-cell lymphoma 2 (Bcl-2) homologous antagonist/killer was increased in response to incubation with pectin. However, incubation with pectin did not affect expression of Bcl-2-associated X protein or Bcl-2, or the caspase-3 activity. Overall, we concluded that pectin reduces the viability of human HT29 colon cancer cells, which is accompanied with a shift in the expression of proteins associated with mitochondrial dynamics towards mitochondrial fusion. Moreover, incubation with pectin favors cellular senescence over apoptosis in HT29 cells.
Collapse
Affiliation(s)
- José Javier Zamorano-León
- Department of Public Health and Maternal and Child Health, School of Medicine, Universidad Complutense de Madrid, Madrid 28040, Spain
| | - Sandra Ballesteros
- Department of Physiology, School of Medicine, Universidad Complutense de Madrid, Madrid 28040, Spain
| | - Natalia de Las Heras
- Department of Physiology, School of Medicine, Universidad Complutense de Madrid, Madrid 28040, Spain
| | - Luis Alvarez-Sala
- Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid 28040, Spain.,Internal Medicine Unit, Hospital General Universitario Gregorio Marañon, Madrid 28007, Spain
| | - Mariano de la Serna-Soto
- Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid 28040, Spain
| | - Khaoula Zekri-Nechar
- Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid 28040, Spain
| | - Gala Freixer
- Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid 28040, Spain
| | - Bibiana Calvo-Rico
- Physical Activity and Sport Sciences Department, School of Sport Sciences, Universidad de Castilla-La Mancha, Toledo 13071, Spain
| | - Zhengguang Yang
- Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid 28040, Spain
| | - José Manuel García-García
- Physical Activity and Sport Sciences Department, School of Sport Sciences, Universidad de Castilla-La Mancha, Toledo 13071, Spain
| | - Vicente Lahera
- Department of Physiology, School of Medicine, Universidad Complutense de Madrid, Madrid 28040, Spain
| | - Antonio José López-Farré
- Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid 28040, Spain
| |
Collapse
|
3
|
Vadgama N, Lamont D, Hardy J, Nasir J, Lovering RC. Distinct proteomic profiles in monozygotic twins discordant for ischaemic stroke. Mol Cell Biochem 2019; 456:157-165. [PMID: 30694515 DOI: 10.1007/s11010-019-03501-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Accepted: 01/19/2019] [Indexed: 01/13/2023]
Abstract
Stroke is a common disorder with significant morbidity and mortality, and complex aetiology involving both environmental and genetic risk factors. Although some of the major risk factors for stoke, such as smoking and hypertension, are well-documented, the underlying genetic and detailed molecular mechanisms remain elusive. Exploring the relevant biochemical pathways may contribute to the clinical diagnosis of stroke and shed light on its aetiology. A comparative proteomic analysis of blood serum of a pair of monozygotic (MZ) twins discordant for ischaemic stroke (IS) was performed using a label-free quantitative proteomics approach. To overcome the limit of reproducibility in the serum preparation, two separate runs were performed, each consisting of three technical replicates per sample. Biological processes associated with proteins differentially expressed between the twins were explored with gene ontology (GO) classification using the functional analysis tool g:Profiler. ANOVA test performed in Progenesis LC-MS identified 179 (run 1) and 209 (run 2) proteins as differentially expressed between the affected and unaffected twin (p < 0.05). Furthermore, the level of serum fibulin 1, an extracellular matrix protein associated with arterial stiffness, was on average 13.37-fold higher in the affected twin. Each dataset was then analysed independently, and the proteins were classified according to GO terms. The categories overrepresented in the affected twin predominantly corresponded to stroke-relevant processes, including wound healing, blood coagulation and haemostasis, with a high proportion of the proteins overexpressed in the affected twin associated with these terms. By contrast, in the unaffected twin diagnosed with atopic dermatitis, there were increased levels of keratin proteins and GO terms associated with skin development. The identification of cellular pathways enriched in IS as well as the upregulation of fibulin 1 sheds new light on the underlying disease-causing mechanisms at the molecular level. Our findings of distinct proteomic signatures associated with IS and atopic dermatitis suggest proteomic profiling could be used as a general approach for improved diagnostic, prognostic and therapeutic strategies.
Collapse
Affiliation(s)
- Nirmal Vadgama
- Institute of Neurology, University College London, London, UK
- Cell Biology and Genetics Research Centre, St. George's University of London, London, UK
| | - Douglas Lamont
- College of Life Sciences, University of Dundee, Dundee, UK
| | - John Hardy
- Institute of Neurology, University College London, London, UK
| | - Jamal Nasir
- Cell Biology and Genetics Research Centre, St. George's University of London, London, UK.
- Molecular Biosciences Research Group, Faculty of Health & Society, University of Northampton, Northampton, UK.
| | - Ruth C Lovering
- Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, London, UK
| |
Collapse
|
4
|
Bowlt Blacklock K, Birand Z, Biasoli D, Fineberg E, Murphy S, Flack D, Bass J, Di Palma S, Blackwood L, McKay J, Whitbread T, Fox R, Eve T, Beaver S, Starkey M. Identification of molecular genetic contributants to canine cutaneous mast cell tumour metastasis by global gene expression analysis. PLoS One 2018; 13:e0208026. [PMID: 30566430 PMCID: PMC6300220 DOI: 10.1371/journal.pone.0208026] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2018] [Accepted: 11/10/2018] [Indexed: 12/18/2022] Open
Abstract
Cutaneous mast cell tumours are one of the most common canine cancers. Approximately 25% of the tumours metastasise. Activating c-kit mutations are present in about 20% of tumours, but metastases occur in the absence of mutations. Tumour metastasis is associated with significantly diminished survival in spite of adjuvant chemotherapy. Available prognostic tests do not reliably predict whether a tumour will metastasise. In this study we compared the global expression profiles of 20 primary cutaneous mast cell tumours that metastasised with those of 20 primary tumours that did not metastasise. The objective was to identify genes associated with mast cell tumour metastatic progression that may represent targets for therapeutic intervention and biomarkers for prediction of tumour metastasis. Canine Gene 1.1 ST Arrays were employed for genome-wide expression analysis of formalin-fixed, paraffin-embedded biopsies of mast cell tumours borne by dogs that either died due to confirmed mast cell tumour metastasis, or were still alive more than 1000 days post-surgery. Decreased gene expression in the metastasising tumours appears to be associated with a loss of cell polarity, reduced cell-cell and cell-ECM adhesion, and increased cell deformability and motility. Dysregulated gene expression may also promote extracellular matrix and base membrane degradation, suppression of cell cycle arrest and apoptosis, and angiogenesis. Down-regulation of gene expression in the metastasising tumours may be achieved at least in part by small nucleolar RNA-derived RNA and microRNA-effected gene silencing. Employing cross-validation, a linear discriminant analysis-based classifier featuring 19 genes that displayed two-fold differences in expression between metastasising and non-metastasising tumours was estimated to classify metastasising and non-metastasising tumours with accuracies of 90-100% and 70-100%, respectively. The differential expression of 9 of the discriminator genes was confirmed by quantitative reverse transcription-PCR.
Collapse
Affiliation(s)
| | - Zeynep Birand
- Animal Health Trust, Newmarket, Suffolk, United Kingdom
| | | | | | - Sue Murphy
- Animal Health Trust, Newmarket, Suffolk, United Kingdom
| | - Debs Flack
- Animal Health Trust, Newmarket, Suffolk, United Kingdom
| | - Joyce Bass
- Animal Health Trust, Newmarket, Suffolk, United Kingdom
| | | | - Laura Blackwood
- Institute of Veterinary Science, University of Liverpool, Neston, United Kingdom
| | - Jenny McKay
- IDEXX Laboratories, Ltd, Wetherby, United Kingdom
| | | | - Richard Fox
- Finn Pathologists, Harleston, United Kingdom
| | - Tom Eve
- Finn Pathologists, Harleston, United Kingdom
| | - Stuart Beaver
- Nationwide Laboratory Services, Poulton-le-Fylde, United Kingdom
| | - Mike Starkey
- Animal Health Trust, Newmarket, Suffolk, United Kingdom
| |
Collapse
|
5
|
Moñux G, Zamorano-León JJ, Marqués P, Sopeña B, García-García JM, Laich de Koller G, Calvo-Rico B, García-Fernandez MA, Serrano J, López-Farré A. FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms. Br J Clin Pharmacol 2017; 83:2661-2670. [PMID: 28735510 DOI: 10.1111/bcp.13383] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2016] [Revised: 06/12/2017] [Accepted: 07/09/2017] [Indexed: 11/29/2022] Open
Abstract
AIMS To evaluate if rivaroxaban, an oral factor Xa (FXa) inhibitor, could modify the expression in vitro of inflammatory and oxidative stress biomarkers in abdominal aortic aneurysmal (AAA) sites showing intraluminal thrombus. METHODS AAA sites with intraluminal mural thrombus were obtained from six patients undergoing elective AAA repair. In addition, control abdominal aortic samples were obtained from six organ donors. AAA sites were incubated in the presence and absence of 50 nmol l-1 rivaroxaban. RESULTS AAA sites showing thrombus demonstrated higher content of FXa than control. Interleukin-6 levels released from AAA [Control: median: 23.45 (interquartile range: 16.17-37.15) vs. AAA: median: 153.07 (interquartile range: 100.80-210.69) pg ml-1 mg tissue-1 , P < 0.05] and the expression levels of nitric oxide synthase 2 were significantly higher in AAA than in control. The protein expression level of NADPH oxidase subunits gp67-and gp91-phox, but did not gp47-phox, were also significantly higher in the AAA sites than in control. Addition of rivaroxaban to AAA sites explants significantly reduced the release of interleukin-6 [median: 51.61 (interquartile range: 30.87-74.03) pg ml-1 mg tissue-1 , P < 0.05 with respect to AAA alone] and the content of nitric oxide synthase 2, gp67 and gp91-phox NADPH subunits. The content of matrix metallopeptidase 9 was significantly higher in the AAA sites as compared to control. Rivaroxaban also reduced matrix metallopeptidase 9 content in AAA sites to similar levels to control. CONCLUSIONS FXa inhibition by rivaroxaban exerted anti-inflammatory and antioxidative stress properties in human AAA sites, suggesting a role of FXa in these mechanisms associated with the pathogenesis of AAA.
Collapse
Affiliation(s)
- Guillermo Moñux
- Vascular Surgery Department, Hospital Clínico San Carlos, Madrid, Spain
| | - Jose J Zamorano-León
- Technological Innovation and Clinical Practice University Class (AINTEC), School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
| | - Pablo Marqués
- Vascular Surgery Department, Hospital Clínico San Carlos, Madrid, Spain
| | - Bernardo Sopeña
- Technological Innovation and Clinical Practice University Class (AINTEC), School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
| | - J M García-García
- Physical Activity and Sport Sciences Department, Universidad Castilla-La Mancha, Toledo, Spain
| | | | - Bibiana Calvo-Rico
- Physical Activity and Sport Sciences Department, Universidad Castilla-La Mancha, Toledo, Spain
| | - Miguel A García-Fernandez
- Technological Innovation and Clinical Practice University Class (AINTEC), School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.,Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
| | - J Serrano
- Vascular Surgery Department, Hospital Clínico San Carlos, Madrid, Spain
| | - Antonio López-Farré
- Technological Innovation and Clinical Practice University Class (AINTEC), School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.,Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
| |
Collapse
|
6
|
Perez-Segura P, Zamorano-León JJ, Acosta D, Santos-Sancho JM, Modrego J, Caldés T, de la Hoya M, Díaz-Rubio E, Díaz-Millán I, de Las Heras N, Rico Zalba LA, Lahera V, Melander O, López Farré A. BRCA2 gene mutations and coagulation-associated biomarkers. Thromb Haemost 2015; 115:415-23. [PMID: 26446551 DOI: 10.1160/th15-06-0520] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Accepted: 09/10/2015] [Indexed: 01/01/2023]
Abstract
Thromboembolic events are the second cause of death in cancer patients, although the mechanisms underlying this increased thromboembolic risk remain unclear. The aims of this study were to examine whether BRCA2 gene mutations may modify the circulating levels of thrombocoagulation biomarkers and whether breast cancer development may influence changes in such circulating biomarkers. The study was performed in 25 women with mutations in the BRCA2 gene (n=12 breast cancer, n=13 breast cancer-free) and in 13 BRCA2 non-mutant controls. Results revealed that plasma levels of fibrinogen gamma chain isotypes 2 and 3, haptoglobin isotypes 4 and 5, serotransferrin isotypes 3 and 4 and convertase C3/C5 isotypes 4 and 5 were significantly higher in BRCA2 mutation carriers compared to controls. However, plasma levels of vitamin D binding protein isotype 1 and alpha1-antitrypsin isotypes 2, 3 and 4 were significantly decreased in BRCA2 mutation carriers compared to controls. Plasma expression of PF4 and P-selectin was significantly higher in BRCA2 mutations carriers than in controls. BRCA2 truncated mutations conserving a binding region for RAD51 were associated with increased plasma levels of alpha1-antitrypsin isotypes 3 and 4 with respect to women showing BRCA2 mutations that loss the binding RD51 region to BRCA2. Only plasma levels of vitamin D binding protein isotypes 1 and 3 were significantly reduced and alpha 1-antitrypsin isotype 1 was increased in cancer-free BRCA2 mutation carriers compared to BRCA2 mutation carriers with breast cancer. The presence of BRCA2 mutations is associated with increased plasma levels of thrombo-coagulating-related proteins, which are independent to breast cancer development.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - Antonio López Farré
- Antonio López Farré, Medicine Department, School of Medicine, Plaza Ramón y Cajal. SN, Universidad Complutense de Madrid, Madrid 28040, Spain, E-mail:
| |
Collapse
|
7
|
Melander O, Modrego J, Zamorano-León JJ, Santos-Sancho JM, Lahera V, López-Farré AJ. New circulating biomarkers for predicting cardiovascular death in healthy population. J Cell Mol Med 2015; 19:2489-99. [PMID: 26258425 PMCID: PMC4594690 DOI: 10.1111/jcmm.12652] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2015] [Accepted: 06/08/2015] [Indexed: 01/09/2023] Open
Abstract
There is interest to analyse newer biomarkers to identify healthy individuals at risk to develop cardiovascular disease (CVD) incidents and death. To determine in healthy individuals new circulating protein biomarkers, whose systemic levels may be associated with the risk of future development of CVD incidents and death. The study was performed in 82 individuals from the Malmö Diet and Cancer study cohort, free from CVD of whom 41 developed CVD and 41 did not. Plasma proteins related to inflammation and thrombo-coagulating processes were analysed. α1-antitrypsin isotype 3 plasma levels were significantly higher while apolipoprotein J plasma levels were lower in participants that developed CVD incidents than those that did not develop acute cardiovascular episode. Of 82 participants, 17 died by CVD causes. There were proteins whose expression in plasma was significantly higher in participants suffering CVD death as compared with those that did not die by CVD. These proteins included: fibrinogen β-chain isotypes 1 and 3, fibrinogen-γ-chain isotype 2, vitamin D-binding protein isotypes 1, 2 and 3, α1-antitrypsin isotypes 3 and 6, haptoglobin isotypes 3,4,5 and 5, haemopexin isotypes 1 and 2, and Rho/Rac guanine nucleotide exchange factor 2. Moreover, apolipoprotein J plasma levels were found lower in participants that died by cardiovascular cause. Association between plasma levels of proteins and CVD death was independent of age, gender, conventional risk factors and plasma C-reactive protein levels. Several protein plasma levels and protein isotypes related to inflammation and thrombo-coagulating phenomena were independently associated with the risk of future CVD death.
Collapse
Affiliation(s)
- Olle Melander
- Department of Clinical Sciences, Lund UniversityMalmö, Sweden
| | - Javier Modrego
- Instituto de Investigacion Sanitaria del Hospital Clínico San Carlos (IdISSC)Madrid, Spain
| | - Jose J Zamorano-León
- Instituto de Investigacion Sanitaria del Hospital Clínico San Carlos (IdISSC)Madrid, Spain
| | - Juana M Santos-Sancho
- Department of Preventive Medicine and Public Health, School of Medicine, Universidad ComplutenseMadrid, Spain
| | - Vicente Lahera
- Instituto de Investigacion Sanitaria del Hospital Clínico San Carlos (IdISSC)Madrid, Spain
- Department of Physiology, School of Medicine, Universidad ComplutenseMadrid, Spain
| | - Antonio J López-Farré
- Instituto de Investigacion Sanitaria del Hospital Clínico San Carlos (IdISSC)Madrid, Spain
- Department of Medicine, School of Medicine, Universidad ComplutenseMadrid, Spain
| |
Collapse
|
8
|
de la Sierra A, Pintó X, Guijarro C, Miranda JL, Callejo D, Cuervo J, Subirà R, Rubio M. Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain. Adv Ther 2015; 32:944-61. [PMID: 26499178 PMCID: PMC4635180 DOI: 10.1007/s12325-015-0252-y] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2015] [Indexed: 12/13/2022]
Abstract
Introduction Cardiovascular diseases (CVDs) represent a major Public Health burden. High serum cholesterol levels have been linked to major CV risk. The objectives of this study were to review the epidemiology of hypercholesterolemia in high risk CV patients from Spain, by assessing its prevalence, the proportion of diagnosed patients undergoing pharmacological treatment and the degree of attained lipid control. Methods A systematic literature review was carried out using Medline and two Spanish databases. Manuscripts containing information on hypercholesterolemia in several high CV risk groups [diabetes mellitus (DM), Systematic COronary Risk Evaluation (SCORE) risk >5, or documented CVD], published between January 2010 and October 2014, were included. Results Of the 1947 published references initially retrieved, a full-text review was done on 264 manuscripts and 120 were finally included. Prevalence of hypercholesterolemia ranged from 50 to 84% in diabetics, 30–60% in patients with DM or elevated SCORE risk, 64–74% with coronary heart disease, 40–70% in stroke patients, and 60–80% in those with peripheral artery disease. Despite the finding that most of them were on pharmacological treatment, acceptable control of serum lipids was very variable, ranging from 15% to 65%. Among those with heterozygous familial hypercholesterolemia, 95–100% received treatment but less than 50% achieved their therapeutic goals. Conclusions An elevated prevalence of hypercholesterolemia can be found in targeted groups at high CV risk. Although most patients are receiving pharmacological treatment, rates of lipid control continue to be low, both in primary and secondary prevention. Electronic supplementary material The online version of this article (doi:10.1007/s12325-015-0252-y) contains supplementary material, which is available to authorized users.
Collapse
|
9
|
Sayols-Baixeras S, Lluís-Ganella C, Subirana I, Salas LA, Vilahur N, Corella D, Muñoz D, Segura A, Jimenez-Conde J, Moran S, Soriano-Tárraga C, Roquer J, Lopez-Farré A, Marrugat J, Fitó M, Elosua R. Identification of a new locus and validation of previously reported loci showing differential methylation associated with smoking. The REGICOR study. Epigenetics 2015; 10:1156-65. [PMID: 26829059 PMCID: PMC4844221 DOI: 10.1080/15592294.2015.1115175] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Revised: 10/06/2015] [Accepted: 10/27/2015] [Indexed: 12/31/2022] Open
Abstract
Smoking increases the risk of many diseases and could act through changes in DNA methylation patterns. The aims of this study were to determine the association between smoking and DNA methylation throughout the genome at cytosine-phosphate-guanine (CpG) site level and genomic regions. A discovery cross-sectional epigenome-wide association study nested in the follow-up of the REGICOR cohort was designed and included 645 individuals. Blood DNA methylation was assessed using the Illumina HumanMethylation450 BeadChip. Smoking status was self-reported using a standardized questionnaire. We identified 66 differentially methylated CpG sites associated with smoking, located in 38 genes. In most of these CpG sites, we observed a trend among those quitting smoking to recover methylation levels typical of never smokers. A CpG site located in a novel smoking-associated gene (cg06394460 in LNX2) was hypomethylated in current smokers. Moreover, we validated two previously reported CpG sites (cg05886626 in THBS1, and cg24838345 in MTSS1) for their potential relation to atherosclerosis and cancer diseases, using several different approaches: CpG site methylation, gene expression, and plasma protein level determinations. Smoking was also associated with higher THBS1 gene expression but with lower levels of thrombospondin-1 in plasma. Finally, we identified differential methylation regions in 13 genes and in four non-coding RNAs. In summary, this study replicated previous findings and identified and validated a new CpG site located in LNX2 associated with smoking.
Collapse
Affiliation(s)
- Sergi Sayols-Baixeras
- Cardiovascular Epidemiology and Genetics Research Group; IMIM (Hospital del Mar Medical Research Institute); 08003 Barcelona, Catalonia, Spain
- Universitat Pompeu Fabra (UPF); 08003 Barcelona, Catalonia, Spain
| | - Carla Lluís-Ganella
- Cardiovascular Epidemiology and Genetics Research Group; IMIM (Hospital del Mar Medical Research Institute); 08003 Barcelona, Catalonia, Spain
| | - Isaac Subirana
- Cardiovascular Epidemiology and Genetics Research Group; IMIM (Hospital del Mar Medical Research Institute); 08003 Barcelona, Catalonia, Spain
- CIBER Epidemiology and Public Health; 08003 Barcelona, Catalonia, Spain
| | - Lucas A Salas
- Universitat Pompeu Fabra (UPF); 08003 Barcelona, Catalonia, Spain
- CIBER Epidemiology and Public Health; 08003 Barcelona, Catalonia, Spain
- Centre for Research in Environmental Epidemiology (CREAL); 08003 Barcelona, Catalonia, Spain
| | - Nadia Vilahur
- Centre for Research in Environmental Epidemiology (CREAL); 08003 Barcelona, Catalonia, Spain
| | - Dolores Corella
- Preventive Medicine Department; Genetic and Molecular Epidemiology Unit; University of Valencia; 46010 Valencia, Spain
- CIBER Obesity and Nutrition; 15706 Santiago de Compostela, Galicia, Spain
| | - Dani Muñoz
- Cardiovascular Risk and Nutrition Research Group; IMIM (Hospital del Mar Medical Research Institute); 08003 Barcelona, Catalonia, Spain
| | - Antonio Segura
- Health Sciences Institute; 45600 Talavera de la Reina, Toledo, Spain
| | - Jordi Jimenez-Conde
- Department of Neurology; Neurovascular Research Group; IMIM-Hospital del Mar (Hospital del Mar Medical Research Institute); 08003 Barcelona, Catalonia, Spain
| | - Sebastián Moran
- Cancer Epigenetics and Biology Program (PEBC); Bellvitge Biomedical Research Institute (IDIBELL); 08908 Barcelona, Catalonia, Spain
| | - Carolina Soriano-Tárraga
- Department of Neurology; Neurovascular Research Group; IMIM-Hospital del Mar (Hospital del Mar Medical Research Institute); 08003 Barcelona, Catalonia, Spain
| | - Jaume Roquer
- Department of Neurology; Neurovascular Research Group; IMIM-Hospital del Mar (Hospital del Mar Medical Research Institute); 08003 Barcelona, Catalonia, Spain
| | | | - Jaume Marrugat
- Cardiovascular Epidemiology and Genetics Research Group; IMIM (Hospital del Mar Medical Research Institute); 08003 Barcelona, Catalonia, Spain
| | - Montse Fitó
- CIBER Obesity and Nutrition; 15706 Santiago de Compostela, Galicia, Spain
- Cardiovascular Risk and Nutrition Research Group; IMIM (Hospital del Mar Medical Research Institute); 08003 Barcelona, Catalonia, Spain
| | - Roberto Elosua
- Cardiovascular Epidemiology and Genetics Research Group; IMIM (Hospital del Mar Medical Research Institute); 08003 Barcelona, Catalonia, Spain
| |
Collapse
|
10
|
López-Farré AJ, Modrego J, Azcona L, Guerra R, Segura A, Rodríguez P, Zamorano-León JJ, Lahera V, Macaya C. Nitric oxide from mononuclear cells may be involved in platelet responsiveness to aspirin. Eur J Clin Invest 2014; 44:463-9. [PMID: 24571196 DOI: 10.1111/eci.12252] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2013] [Accepted: 02/24/2014] [Indexed: 12/27/2022]
Abstract
BACKGROUND Several mechanisms have been proposed to explain why some platelets have a reduced response to aspirin (ASA). Among them, it was reported an increased circulating level of vitamin-D-binding protein (DBP). In addition, nitric oxide (NO) released from mononuclear cells was involved in the antiplatelet effects of ASA. The aim was to analyse the relationship between platelet response to ASA and both NO generation and vitamin-D-binding protein content in mononuclear cells. MATERIALS AND METHODS Mononuclear cells were obtained from patients with stable coronary artery disease that were divided by a platelet functionality test (PFA-100) as ASA-sensitive (n=23) and ASA resistant (n=27). RESULTS Both the release of NO (determined by nitrite+nitrate concentration) and the expression of endothelial-type NO synthase (eNOS) were higher in mononuclear cells from ASA sensitive as compared with those from ASA-resistant patients. There was a positive correlation between either the release of NO and the expression of eNOS protein in mononuclear cells with the ability of ASA to inhibit platelet activity. DBP content in mononuclear cells was higher in ASA resistant than in ASA sensitive. The level of DBP content in mononuclear cells was negatively associated with the ability of ASA to inhibit platelets. However, in vitro experiments suggested that there was no association between DBP and NO production by mononuclear cells. CONCLUSIONS Mononuclear cells from patients with platelets with lower responsiveness to ASA showed a reduced ability to produce NO.
Collapse
Affiliation(s)
- Antonio J López-Farré
- Cardiovascular Research Unit, Cardiology Department of Hospital Clínico San Carlos de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Medicine School, Complutense University, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Zamorano-León JJ, Olivier C, de Las Heras N, Mateos-Cáceres PJ, Brime Menéndez R, Rodríguez-Sierra P, Martín Palacios N, Manso LSJ, Modrego J, Segura A, Macaya C, López-Farré AJ. Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin. J Sex Med 2013; 10:3110-20. [PMID: 24112450 DOI: 10.1111/jsm.12324] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
INTRODUCTION Evidences have been suggested that phosphodiesterase type 5 (PDE5) inhibition promotes vasculoprotective benefits in patients with cardiovascular diseases. AIM The aim of this study is to analyze the systemic effect of PDE5 inhibition in type 2 diabetes mellitus patients with erectile dysfunction (ED) determining changes in the expression levels of plasma proteins. METHODS Seventeen patients with controlled type 2 diabetes mellitus and ED were included in the study. Patients received vardenafil hydrochloride 20 mg on demand during 12 weeks. At the beginning and 12 weeks after vardenafil administration, plasma samples were collected and analyzed using proteomics. MAIN OUTCOME MEASURES International Index of Erectile Function-Erectile Function Domain (IIEF-EFD) and plasma protein expression before and after vardenafil administration. Nitrate/nitrite release, PDE5, and soluble guanylate cyclase (sGC) expression and cyclic guanosine monophosphate (cGMP) content in cultured bovine aortic endothelial cells (BAECs). RESULTS The IIEF-EFD score was markedly improved after 12 weeks of vardenafil administration. Plasma levels of alpha 1-antitrypsin isotypes 4 and 6 and β-tropomyosin were decreased, whereas apolipoprotein AI isoype 5 was increased 12 weeks after vardenafil administration. Only β-tropomyosin plasma levels were inversely correlated with IIEF-EFD score. Tropomyosin has been added to cultured BAECs and after 24 hours reduced the protein expression level of sGC-β1 subunit and decreased the cGMP content. Tropomyosin did not modify PDE5 expression and nitric oxide release in BAECs as compared with control BAECs. Vardenafil (10 μg/mL) did not modify sGC-β1 subunit expression in tropomyosin + vardenafil-incubated BAECs; however, vardenafil significantly reversed the reduction of cGMP content induced by tropomyosin. CONCLUSION Vardenafil administration improved erectile functionality in controlled type 2 diabetes mellitus patients with ED, which was associated with reduction of circulating plasma β-tropomyosin levels. Tropomyosin affected by itself the cGMP generating system suggesting a possible new mechanism involved in ED. Vardenafil reversed the reduction effect of cGMP content elicited by tropomyosin in BAECs.
Collapse
Affiliation(s)
- Jose J Zamorano-León
- Cardiovascular Research Unit, Cardiology Department of Hospital Clínico San Carlos de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|